Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Next Previous
Trial Profile

Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosbretabulin (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Mateon Therapeutics

Most Recent Events

  • 15 Nov 2016 Status changed from recruiting to completed.
  • 06 Jan 2016 According to an OXiGENE media release, the US FDA granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors, in January 2016.
  • 05 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top